Challenges in Glycemic Control for Adolescents with Type 2 Diabetes

Metformin plus rosiglitazone bested metformin monotherapy, but failure rates for all tested regimens were disappointingly high.

To address the persistent challenge of maintaining glycemic control in adolescents with type 2 diabetes, researchers compared three treatment options. The participants were 699 teenagers (age range, 10–17 years) with type 2 diabetes, body-mass index (BMI) in the 85^th percentile, a negative test for diabetes-related autoantibodies, and a fasting C-peptide level >0.6 ng/mL.

After maintaining a glycated hemoglobin level <8% for ≥2 months on metformin monotherapy, participants were randomized to continue receiving metformin alone, to receive metformin plus rosiglitazone (a thiazolidinedione that increases fat cells' sensitivity to insulin), or to receive metformin plus a lifestyle intervention. Mean follow-up was about 4 years.

Treatment failure …

Reviewing Author

F. Bruder Stapleton, MD

Disclosures

Consultant/Advisory BoardCareer Physician

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesAmerican Society of Pediatric Nephrology Foundation (Chair)

F. Bruder Stapleton, MD

Disclosures

Consultant/Advisory BoardCareer Physician

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesAmerican Society of Pediatric Nephrology Foundation (Chair)

Challenges in Glycemic Control for Adolescents with Type 2 Diabetes

Topics

Reviewing Author